ReShape Lifesciences Inc. Common Stock
RSLS
RSLS was delisted on the 28th of December, 2018.
11 hedge funds and large institutions have $818K invested in ReShape Lifesciences Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 6 closing their positions.
8% less funds holding
Funds holding: 12 → 11 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
91% less capital invested
Capital invested by funds: $9.13M → $818K (-$8.31M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.44M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$101K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$31.6K |
| 4 |
RWP
RWA Wealth Partners
Newton,
Massachusetts
|
+$10.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$9.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NLVP
New Leaf Venture Partners
New York
|
-$3.77M |
| 2 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$3.26M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$38K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$28K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$27K |
RSLS Hedge Fund Activity: Q2 2018 in Review
11 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in ReShape Lifesciences Inc. Common Stock (RSLS) for Q2 2018, worth a combined $818K — down 91% from $9.13M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of RSLS and 5 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 3 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.44M. The largest seller was New Leaf Venture Partners, exiting entirely with an estimated $3.77M sold.
- 11 institutional investors held ReShape Lifesciences Inc. Common Stock (RSLS) as of Q2 2018, down from 12 in Q1 2018.
- Funds reported $818K of ReShape Lifesciences Inc. Common Stock stock for Q2 2018, down 91% quarter-over-quarter.
- 5 funds opened new ReShape Lifesciences Inc. Common Stock positions in Q2 2018 and 6 closed out, a net change of -1 holder.
- The largest ReShape Lifesciences Inc. Common Stock buyer in Q2 2018 was Sabby Management, an estimated $1.44M added.
- The largest ReShape Lifesciences Inc. Common Stock seller in Q2 2018 was New Leaf Venture Partners, an estimated $3.77M sold.
Based on aggregated 13F filings for Q2 2018.